Venture tracks

Amy Schulman joined Polaris Partners as a venture partner. Schulman also became CEO of Polaris portfolio company Arsia Therapeutics Inc., which is developing excipients that reduce the viscosity of biologics allowing them to be injected subcutaneously. Schulman was general counsel and EVP at Pfizer Inc. (NYSE:PFE) and was business unit lead of the pharma's consumer healthcare business...